RecruitingNCT06279104

A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary

Sponsor

Tongji Hospital

Enrollment

150 participants

Start Date

Mar 1, 2023

Study Type

OBSERVATIONAL

Conditions

Ovarian Clear Cell Carcinoma

Summary

The goal of this observational study is to learn about the treatment effectiveness of physician's choice of chemotherapy and the immune checkpoint inhibitor (ICI)-based therapy in patients with relapsed/refractory ovarian clear cell carcinoma (OCCC), and compare the treatment response with the phase II, single-arm clinical trial INOVA to investigate the efficacy of combinational therapy of sintilimab plus bevacizumab. The main questions it aims to answer are: * What is the efficacy of physician's choice of chemotherapy in relapsed/refractory OCCC patients in the real world? * Is ICI-based therapy more effective than physician's choice of chemotherapy in real-world for relapsed/refractory OCCC patients? * Dose the combinational regimens of sintilimab plus bevacizumab in Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma (INOVA) trial more effective than physician's choice of chemotherapy? Participants will be respectively retrieved and extracted de-identified, longitudinal electronic health records (EHR)-derived data.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This observational study is comparing different real-world treatment approaches used for ovarian clear cell carcinoma — a less common and often chemotherapy-resistant type of ovarian cancer — to identify which strategies produce the best outcomes. **You may be eligible if...** - You are a woman between 18 and 75 years old - You have a confirmed diagnosis of ovarian clear cell carcinoma - If your cancer has recurred or persisted, you have already received at least one platinum-based chemotherapy regimen - Your general health is acceptable (ECOG ≤2) - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - Your tumor is not confirmed as ovarian clear cell carcinoma on pathology (e.g., it originates elsewhere) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGphysician's choice of chemotherapy

physician's choice of chemotherapy for relapsed/refractory ovarian clear cell carcinoma

DRUGimmune checkpoint inhibitor based therapy

immune checkpoint inhibitor based therapy for relapsed/refractory ovarian clear cell carcinoma

Locations(1)

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06279104

Related Trials

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

NCT060654621 location

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

NCT0410477660 locations